Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View
by Zacks Equity Research
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.
Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.
CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook
by Zacks Equity Research
CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
by Zacks Equity Research
Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.
IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.
Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.
Intuitive Surgical (ISRG) Rises 5% Post Earnings: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
Intuitive Surgical and American Airlines Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuitive Surgical and American Airlines Industries have been highlighted as Zacks Bull and Bear of the Day
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
by Zacks Equity Research
Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Bull of the Day: Inuitive Surgical (ISRG)
by Andrew Rocco
Intuitive Surgical is a leading innovator in robotic-assisted surgery with its da Vinci Surgical System. The company benefits from an aging population and a solid competitive moat.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.
Is Trending Stock Intuitive Surgical, Inc. (ISRG) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook
by Zacks Equity Research
Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.
ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.
Labcorp (LH) Q2 Earnings Surpass Estimates (revised)
by Mark Vickery
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Labcorp (LH) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.
Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.
QIAGEN (QGEN) Q2 Earnings Surpass Estimates, Margins Crash
by Zacks Equity Research
QIAGEN's (QGEN) earnings and revenues beat estimates in the second quarter. The company remains bullish on solid growth trends in the core business.
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
by Zacks Equity Research
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Neogen (NEOG) Q4 Earnings Miss Estimates, Margins Crash
by Zacks Equity Research
Neogen's (NEOG) Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the fourth quarter of fiscal 2024.